Vaxcyte, Inc. (PCVX)
NASDAQ: PCVX · Real-Time Price · USD
31.45
+2.45 (8.45%)
May 8, 2025, 4:00 PM EDT - Market closed
Vaxcyte Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Vaxcyte stock have an average target of 136.5, with a low estimate of 90 and a high estimate of 163. The average target predicts an increase of 334.02% from the current stock price of 31.45.
Analyst Consensus: Strong Buy
* Price targets were last updated on Apr 8, 2025.
Analyst Ratings
The average analyst rating for Vaxcyte stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 6 | 6 | 6 | 6 |
| Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Hold | 1 | 1 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Apr 22, 2025 |
| Needham | Needham | Strong Buy Reiterates $90 | Strong Buy | Reiterates | $90 | +186.17% | Apr 8, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $138 → $100 | Strong Buy | Maintains | $138 → $100 | +217.97% | Apr 1, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $157 → $137 | Strong Buy | Maintains | $157 → $137 | +335.61% | Apr 1, 2025 |
| Needham | Needham | Strong Buy Maintains $140 → $90 | Strong Buy | Maintains | $140 → $90 | +186.17% | Apr 1, 2025 |
Financial Forecast
Revenue This Year
n/a
from 2.07B
Revenue Next Year
n/a
EPS This Year
-4.61
from -3.80
EPS Next Year
-4.56
from -4.61
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | 346.5M | ||
| Avg | n/a | n/a | 93.1M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.64 | -2.51 | -1.96 | ||
| Avg | -4.61 | -4.56 | -4.45 | ||
| Low | -5.49 | -5.39 | -5.95 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.